Poster Sessions
Poster Session I
PARKINSON’S DISEASE: BIOMARKERS AND GENETICS
Patients —Mahsa Dolatshahi, Seyyed
P1.001 Genome-wide Association for
P1.012 Lewy Body and Tau pathology
the Park10 Locus in Iopathic, Autopsyproven, Lewy Body Parkinson Disease and Autopsy-Proven Controls —Jeffery
Vance, Karen Nuytemans, Lissette Gomez, William Scott, Gary Beecham, Djordje Gveric, Eden Martin, APDGC Consortium
P1.002 Genetic analysis of the
Glucocerebrosidase gene in Indian patients with Parkinson’s disease —Ravi YADAV, Saketh Kapoor, Mayank Madhukar, Rajini Manja, Pramod Pal, Arun Kumar
P1.003 Interplay Between LRRK2 Action in Neurons and Macrophages in Mediating α-Synuclein linked Neurodegeneration —Hisham
Abdelmotilib, Andrew West, Laura VolpicelliDaly, Ashley Harms
Shayan PourMirbabaei, Mehdi Yaseri, Aida Kamalian, Mohammad Hadi Aarabi
in a patient with parkinsonism, cognitive decline, rapid progression and the GBA1 T369M variant —Hannah Walters, Rachel Saunders-Pullman, John Crary, Deborah Raymond, Susan Bressman
Thomas Beach, Tatiana Foroud, Charles Adler, Holly Riss, Dixie Ecklund, Chelsea CaspellGarcia, Kuldip Dave, Sampada Deshpande, Shirley Lasch, Vanessa Arnedo, Lindsey Riley, Danna Jennings, Brit Mollenhauer, Lama Chahine
Houghton
P1.005 Baseline Cerebrospinal Fluid
P1.015 Neurons with oscillatory
Biomarkers Associated with Longitudinal Cognitive and Functional Decline in Early Parkinson’s Disease —Olga Kofman, David
activity in the basal ganglia and the ventral thalamus in patients with Parkinson’s disease —Ping Zhuang, Mark
Wolk, Corey McMillan
Hallett, Gang Du, Yuqing Zhang, Yongjie Li
P1.006 Elevated GM3 Plasma
P1.016 Objective gait parameters as
Chan, Adler Perotte, Bowen Zhou, Christopher Liong, Evan Shorr, Karen Marder, Un Kang, Cheryl Waters, Oren Levy, Yimeng Xu, Hong Bin Shim, Itsik Pe’er, Gilbert Di Paolo
Tuhin Virmani
SUNDAY
and Plasma-Based miRNA Levels in Parkinson’s disease Patients —Dominic
Facciponte, Jackson Storm, Haley Grigel, Jacob Rauh, Patricia Henegan, Angeline Andrew, Mary Feldman, Stephen Lee, Elijah Stommel
P1.008 Functional MAOB gene
intron 13 polymorphism predicts putaminal dopamine turnover in de novo Parkinson’s disease —Matthias Lohle, Graziella Mangone, Martin Wolz, Bettina Beuthien-Baumann, Liane Oehme, Jorg Van Den Hoff, Jorg Kotzerke, Heinz Reichmann, Jean Christophe Corvol, Alexander Storch
P1.009 Serum Oxidant and
Antioxidant Status of Patients with Parkinson’s Disease —Mustafa Yurtdas,
Tahir Kurtulus Yoldas, Burcu Gokce Cokal, Nalan Gunes, Zahide Esra Durak, Selda Keskin Guler, Bilal Aytac, Ilker Durak, Mehmet Ilker Yon, Aysegul Akyuz, Ufuk Atak Donger
P1.010 Enteric neurons reveal
substantial ex vivo mitochondrial changes in Parkinson’s disease —
Paul Antony, Aidos Baumuratov, Marek Ostaszewski, Feng He, Luis Salamanca, Laurent Antunes, Jos Weber, Laura Longhino, Pascal Derkinderen, Rudi Balling, Werner Koopman, Nico Diederich
P1.011 An Exploratory Study of
Associations Between longitudinal Changes of different CSF Biomarkers in Early, Drug-naïve Parkinson’s Disease
P1.145–222
G
P1.223–250
D
P1.101–110
Poster Discussion
C
P1.081–100
P1.014 Comparison of quantitative
Theresa Bartels, Susan Lindquist
P1.007 Environmental Risk Factors
F
E
P1.111–144
Multisite Tissue and Biofluid Sampling for Synuclein in Parkinson’s Disease: The Systemic Synuclein Sampling Study (S4) —Carly Linder, Christopher Coffey,
measures of Pupil Light Reflex measured using Automated Pupillometer in patients with Parkinson’s disease and controls —Robin Ulep, Fawad Khan, David
Concentration in Parkinson’s Disease: a Lipidomics Analysis —Roy Alcalay, Robin
Poster Session I Neighborhoods
P1.013 Feasibility and Safety of
Networks Mechanistically Link Alphasynuclein to Diverse Genetic Risk Factors for Parkinsonism —Vikram Khurana,
P1.004 Proteome-scale Molecular
Sunday, April 23 8:30 a.m.—5:30 p.m.
H
B
P1.251–328
P1.031–070 ePosters
P1.071–080
I
P1.329–412
a noninvasive biomarker for freezing of gait in Parkinson disease —Jesal Shah,
PARKINSON’S DISEASE: THERAPEUTICS AND TELEHEALTH I
P1.017 Efficacy of sublingual
apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: results from the Phase 3 study dose-titration phase —Robert Hauser, Stuart Isaacson,
Alberto Espay, Rajesh Pahwa, Daniel Truong, Eric Pappert, Peter Gardzinski, Bruce Dzyngel, Albert Agro, Hubert Fernandez
P1.018 Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson’s Disease —
Christopher Goetz, Glenn Stebbins, Kathryn Chung, Anthony Nicholas, Robert Hauser, Mark Stacy, Kathleen Shannon
A
P1.001–030 A: Movement Disorders B: Research Methodology and Education; Practice, Policy, and Ethics; Movement Disorders ePosters C: Aging and Dementia D: Movement Disorders Poster Discussion E: Neuromuscular and Clinical Neurophysiology (EMG) F: General Neurology; Neuro-oncology; Headache; Pain and Palliative Care G: Epilepsy/Clinical Neurophysiology (EEG) H: Cerebrovascular Disease and Interventional Neurology; Infectious Disease I: MS and CNS Inflammatory Disease
P1.019 Identification of the Carbidopa Concentration in Subcutaneously Administered ND0612 (Levodopa/ Carbidopa) that Provides Optimal Levodopa Bioavailability —Liat Adar, Tami Rachmilewitz, Sheila Oren
P1.020 Duration of “on” periods after treatment with extended-release vs. immediate-release carbidopa-levodopa in patients with advanced Parkinson’s disease —William Ondo, Margery Mark, Nishit Modi, Sarita Khanna, Suneel Gupta
P1.021 Pooled Analysis of Phase
3 studies of ADS-5102 (amantadine hydrochloride) extended release capsules for Levodopa-Induced Dyskinesia: A detailed review of PD Home Diary Results —Caroline Tanner,
78 2017 AAN Annual Meeting Scientific Program
Rajesh Pahwa, Robert Hauser, Stuart Isaacson, Reed Johnson, Larissa Felt, Mary Jean Stempien
Isaacson, Alberto Espay, Rajesh Pahwa, Daniel Truong, Eric Pappert, Peter Gardzinski, Bruce Dzyngel, Albert Agro, Robert Hauser
P1.022 Rotigotine transdermal
P1.024 Effect of levodopa-carbidopa
Kawabe, Takanori Takazawa, Takehisa Hirayama, Masaru Yanagihashi, Ken Miura, Yuichi Ishikawa, Junya Ebina, Maya Kyuzen, Tetsuro Nagaoka, Masahiro Sawada, Sayori Hanashiro, Harumi Morioka, Yasuo Iwasaki
Poewe, David Standaert, Cindy Zadikoff, Stephanie Dubow, Lars Bergmann, Ashley Yegin, Coleen Hall, Vanessa Felipe, Weining Robieson, Luigi Barbato
patch attenuates freezing of gait during wearing off in patients with Parkinson’s disease —Ken Ikeda, Osamu Kano, Kiyokazu
P1.023 Disease severity does not predict effective ON-turning dose of apomorphine sublingual film (APL130277) in patient with Parkinson’s disease —Hubert Fernandez, Stuart
intestinal gel on dyskinesia: design of an open-label, randomized multicenter 12-week study in advanced Parkinson’s disease patients —Angelo Antonini, Werner
P1.025 ND0612—a Newly
Developed Liquid Levodopa/Carbidopa Formulation Administered Continuously Subcutaneously by a Mini-pump—